Technical Report Healthcare Technology Pathology Podiatry
Rethinking glycaemic control in patients on haemodialysis: the role of continuous glucose monitoring

Rethinking glycaemic control in patients on haemodialysis: the role of continuous glucose monitoring

Authors

Lucas Ibrahim

Lucas Ibrahim

Karolinska University Hospital, Antarctica

Amira Rahman

Amira Rahman

Charité Berlin, Brunei

James Kim

James Kim

Cleveland Clinic Abu Dhabi, Qatar

Aisha Nakamura

Aisha Nakamura

St Thomas' Hospital, Congo

Corresponding

Published

February 18, 2026

Paper ID

PAP-000054

Status

Published

DOI

10.65712/tmj.test000312

Rethinking glycaemic control in patients on haemodialysis: the role of continuous glucose monitoring

Advance Services

Create Content

Video • Presentation • Poster

From $97.00 per format

Abstract

Background: Practice around continuous glucose monitoring varies widely between centres. Methods: Eligible participants were patients on haemodialysis. Results: 2791 participants were included (median age 82 years). 146 participants were included (median age 70 years). Conclusion: Strengths include the sample size and blinded outcome assessment.

Introduction

Practice around continuous glucose monitoring varies widely between centres. Earlier studies of continuous glucose monitoring were small or single-centre.

The cost of glycaemic control to health systems is substantial. Practice around continuous glucose monitoring varies widely between centres. Earlier studies of continuous glucose monitoring were small or single-centre.

The cost of glycaemic control to health systems is substantial. glycaemic control remains a leading cause of avoidable harm among patients on haemodialysis.

Guidelines make only a weak recommendation on continuous glucose monitoring. Earlier studies of continuous glucose monitoring were small or single-centre.

Discussion

Implementation will depend on staffing, cost and local protocols.

Residual confounding cannot be excluded. These findings suggest that continuous glucose monitoring is associated with better glycaemic control in patients on haemodialysis. Implementation will depend on staffing, cost and local protocols.

Residual confounding cannot be excluded. Future work should test continuous glucose monitoring in a pragmatic multicentre trial.

These findings suggest that continuous glucose monitoring is associated with better glycaemic control in patients on haemodialysis. Future work should test continuous glucose monitoring in a pragmatic multicentre trial.

Conclusions

Continuous glucose monitoring should be considered for patients on haemodialysis to improve glycaemic control.

References

1. Kim U, Osei W, et al. Tranexamic acid and patient satisfaction. Eur Heart J. 2016;265(2):83-1771.

2. Rossi K, Larsen W, et al. Tranexamic acid and emergency department revisits. BMC Med. 2012;142(10):476-1135.

3. Larsen B, Moreau L, et al. Early enteral nutrition and time to diagnosis. Diabetes Care. 2022;83(5):233-1580.

4. Andersen H, Mueller U, et al. Continuous glucose monitoring and emergency department revisits. Eur Heart J. 2016;159(6):721-1239.

5. Volkov L, Novak A, et al. Continuous glucose monitoring and chronic pain scores. Lancet. 2015;51(6):850-1113.

6. Tanaka M, Okafor W, et al. Tranexamic acid and emergency department revisits. Pediatrics. 2011;79(7):123-1142.

7. Ibrahim Y, Zhang H, et al. Tranexamic acid and health-related quality of life. N Engl J Med. 2022;31(8):517-1521.

8. Patel E, Lindqvist U, et al. Low-dose aspirin and acute kidney injury. Eur Heart J. 2021;357(8):787-1732.

Appendices

Supplementary tables are available on request.

Materials and Methods

Analyses were adjusted for age, sex and baseline severity. The primary outcome was glycaemic control, assessed blind to allocation. Eligible participants were patients on haemodialysis. We conducted a multicentre observational study across 4 centres between 2016 and 2022.

Missing data were handled with multiple imputation. Eligible participants were patients on haemodialysis.

Results

2001 participants were included (median age 77 years). The adjusted odds ratio was 0.82 (95% CI 0.33 to 0.70).

1443 participants were included (median age 38 years). The adjusted odds ratio was 0.74 (95% CI 0.39 to 0.88). The adjusted odds ratio was 0.39 (95% CI 0.31 to 0.67).

GroupnEventsRate %
Female211628.9
Female498139.4
Control153112.8
Centre A4694320.2
Intervention1488235.6
Age < 658253017.9
Age < 653806422.3
TABLE 1: Subgroup analysis
Values are n (%) unless stated otherwise.
Figure 1
FIGURE 1: Kaplan–Meier curve for glycaemic control
Shown for patients on haemodialysis; error bars are 95% confidence intervals.

Effects were consistent across prespecified subgroups. 541 participants were included (median age 56 years). 2934 participants were included (median age 49 years).